• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于微小RNA的常染色体显性多囊肾病治疗方法:从成人到儿童证据的挑战与见解

A miRNA-Based Approach in Autosomal Dominant Polycystic Kidney Disease: Challenges and Insights from Adult to Pediatric Evidence.

作者信息

Vitulano Caterina, Forcina Gianmario, Colosimo Simone, Frattolillo Vittoria, Villani Annalisa Valentina, Marzuillo Pierluigi, Miraglia Del Giudice Emanuele, Di Sessa Anna

机构信息

Department of Woman, Child, and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Via L. De Crecchio, 4, 80138, Naples, Italy.

出版信息

Mol Diagn Ther. 2025 Mar;29(2):183-193. doi: 10.1007/s40291-024-00761-7. Epub 2025 Jan 17.

DOI:10.1007/s40291-024-00761-7
PMID:39820940
Abstract

Autosomal dominant polycystic kidney disease (ADPKD) represents the most common inherited kidney disorder leading to kidney failure in a significant percentage of patients over time. Although previously considered as an adult disease, robust evidence demonstrated that clinical manifestations might occur during childhood and adolescence. Therefore, early identification and treatment of the disease are of cardinal importance for pediatricians to ensure the best long-term outcomes. To date, licensed treatment options are limited but promising potential therapeutic targets are emerging. Among these, an intriguing pathophysiological role for microRNAs as small molecules with a critical role in regulating gene expression has been considered possible in ADPKD. Indeed, numerous circulating microRNAs have been found to be dysregulated in ADPKD, suggesting their potential role as biomarkers and therapeutic targets. Based on this background, further detailed insights into the mechanisms of miRNAs contributing to ADPKD development might pave the way for their effective application as a targeted treatment in young patients with ADPKD. We aimed to summarize the most recent evidence in this fascinating research area, providing a comprehensive overview of the current landscape of specific microRNAs in ADPKD as a potential innovative therapeutic strategy for these young patients.

摘要

常染色体显性多囊肾病(ADPKD)是最常见的遗传性肾脏疾病,随着时间的推移,相当一部分患者会因此导致肾衰竭。尽管以前被认为是一种成人疾病,但有力证据表明,临床表现可能在儿童期和青少年期出现。因此,疾病的早期识别和治疗对儿科医生至关重要,以确保获得最佳的长期预后。迄今为止,获批的治疗选择有限,但有潜力的治疗靶点正在不断涌现。其中,微小RNA作为在调节基因表达中起关键作用的小分子,在ADPKD中可能具有有趣的病理生理作用。事实上,已发现许多循环微小RNA在ADPKD中表达失调,表明它们作为生物标志物和治疗靶点的潜在作用。基于这一背景,进一步深入了解微小RNA促成ADPKD发展的机制,可能为其在ADPKD年轻患者中作为靶向治疗的有效应用铺平道路。我们旨在总结这一引人入胜的研究领域的最新证据,全面概述ADPKD中特定微小RNA的现状,作为这些年轻患者潜在的创新治疗策略。

相似文献

1
A miRNA-Based Approach in Autosomal Dominant Polycystic Kidney Disease: Challenges and Insights from Adult to Pediatric Evidence.基于微小RNA的常染色体显性多囊肾病治疗方法:从成人到儿童证据的挑战与见解
Mol Diagn Ther. 2025 Mar;29(2):183-193. doi: 10.1007/s40291-024-00761-7. Epub 2025 Jan 17.
2
Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline.尿液微小RNA作为常染色体显性多囊肾病进展的潜在生物标志物:基线时微小RNA谱的描述
PLoS One. 2014 Jan 29;9(1):e86856. doi: 10.1371/journal.pone.0086856. eCollection 2014.
3
Therapeutic microRNAs in polycystic kidney disease.多囊肾病中的治疗性微小RNA
Curr Opin Nephrol Hypertens. 2017 Jul;26(4):282-289. doi: 10.1097/MNH.0000000000000333.
4
Urinary MicroRNAs, Possible Biomarkers for Early Detection of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).尿 MicroRNAs,一种用于检测常染色体显性多囊肾病(ADPKD)患者的早期生物标志物。
Iran J Kidney Dis. 2023 Mar;1(2):73-78.
5
The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.儿童和青少年常染色体显性多囊肾病的谱系
Pediatr Nephrol. 2017 Jan;32(1):31-42. doi: 10.1007/s00467-016-3364-y. Epub 2016 Mar 31.
6
Safe Nanocomposite-Mediated Efficient Delivery of MicroRNA Plasmids for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapy.安全纳米复合物介导的微小 RNA 质粒高效传递用于常染色体显性多囊肾病 (ADPKD) 治疗。
Adv Healthc Mater. 2019 Mar;8(5):e1801358. doi: 10.1002/adhm.201801358. Epub 2019 Jan 23.
7
Tiny Non-coding RNAs in Body Fluids, Possible Biomarkers for Autosomal Dominant Polycystic Kidney Disease.体液中的微小非编码RNA,可能是常染色体显性多囊肾病的生物标志物。
Iran J Kidney Dis. 2019 May;13(3):151-164.
8
Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease.人类尿液外泌体中的全球微小RNA谱揭示了常染色体显性多囊肾病的新型疾病生物标志物和细胞途径。
Kidney Int. 2020 Aug;98(2):420-435. doi: 10.1016/j.kint.2020.02.008. Epub 2020 Mar 6.
9
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.常染色体显性多囊肾病:近期遗传学和临床进展概述
Ren Fail. 2025 Dec;47(1):2492374. doi: 10.1080/0886022X.2025.2492374. Epub 2025 Apr 23.
10
Autosomal dominant polycystic kidney disease: genetics, mutations and microRNAs.常染色体显性多囊肾病:遗传学、突变与微小RNA
Biochim Biophys Acta. 2011 Oct;1812(10):1202-12. doi: 10.1016/j.bbadis.2011.03.002. Epub 2011 Mar 17.

本文引用的文献

1
Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights.常染色体显性遗传多囊肾病的研究药物:临床前和早期研究的见解。
Expert Opin Investig Drugs. 2024 May;33(5):469-484. doi: 10.1080/13543784.2024.2342327. Epub 2024 Apr 21.
2
Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement.常染色体显性遗传性多囊肾病:肾外表现。
Int J Mol Sci. 2024 Feb 22;25(5):2554. doi: 10.3390/ijms25052554.
3
Global analysis of urinary extracellular vesicle small RNAs in autosomal dominant polycystic kidney disease.
常染色体显性多囊肾病中外泌体小 RNA 的全球分析。
J Gene Med. 2024 Feb;26(2):e3674. doi: 10.1002/jgm.3674.
4
Mortality risk in patients with autosomal dominant polycystic kidney disease.常染色体显性遗传多囊肾病患者的死亡风险。
BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3.
5
The Pathophysiology of Inherited Renal Cystic Diseases.遗传性肾脏囊性疾病的病理生理学。
Genes (Basel). 2024 Jan 11;15(1):91. doi: 10.3390/genes15010091.
6
Management of Hypertension and Associated Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease.常染色体显性遗传多囊肾病相关高血压及心血管疾病的管理。
Adv Kidney Dis Health. 2023 Sep;30(5):417-428. doi: 10.1053/j.akdh.2023.03.004.
7
Cardiovascular Involvement in Patients with Autosomal Dominant Polycystic Kidney Disease: A Review.常染色体显性遗传多囊肾病患者的心血管受累:综述。
Kidney Blood Press Res. 2024;49(1):9-19. doi: 10.1159/000529119. Epub 2023 Dec 14.
8
Cystic Kidney Diseases in Children and Adults: Differences and Gaps in Clinical Management.儿童及成人的囊性肾病:临床管理中的差异与差距
Semin Nephrol. 2023 Jul;43(4):151434. doi: 10.1016/j.semnephrol.2023.151434. Epub 2023 Nov 22.
9
Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease-The Promised Land?尿液生物标志物在监测常染色体显性遗传性多囊肾病的进展和治疗中的应用——是否充满希望?
Medicina (Kaunas). 2023 May 10;59(5):915. doi: 10.3390/medicina59050915.
10
Autosomal Dominant Polycystic Kidney Disease in Children and Adolescents: Assessing and Managing Risk of Progression.常染色体显性遗传性多囊肾病患儿和青少年:评估和管理进展风险。
Adv Kidney Dis Health. 2023 May;30(3):236-244. doi: 10.1053/j.akdh.2023.01.007.